MedElevator Войти в исследования
← Поиск публикаций

DOI 10.37765/ajmc.2021.88706

Медицинская библиотека · The American journal of managed care · 2021

Association of physician specialty with psoriatic arthritis treatment and costs.

Maksabedian Hernandez Ervant J, Tkacz Joseph, Zimmerman Nicole M, Chan Philip, Limone Brendan, Ogdie Alexis, Karis Elaine, Stolshek Bradley

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To describe current psoriatic arthritis treatment and costs by provider specialty using real-world claims data.

STUDY

DESIGN

Observational, retrospective cohort study of patients in the IBM MarketScan Commercial and supplemental Medicare databases.

METHODS

Eligible patients had newly diagnosed psoriatic arthritis with 12 months of continuous enrollment pre- and post index date for their initial claim. Patients were assigned to 1 of 5 provider specialty cohorts. During the 1-year follow-up period, we collected psoriatic arthritis treatment agent and regimen type and total annual medical and health care costs. We used multivariate regression models to determine the conditional associations of provider specialty with costs.

RESULTS

A total of 2132 patients with incident psoriatic arthritis qualified. Most providers were rheumatologists (n = 1365; 64%). Rheumatologists commonly prescribed oral small molecules (methotrexate, 56.3% of prescriptions; sulfasalazine, 8.6%; apremilast, 7.0%) as the index therapy, whereas 23.8% of prescriptions were for tumor necrosis factor inhibitors (adalimumab, 14.2%; etanercept, 7.9%; and infliximab, 1.7%). Compared with other specialists, dermatologists prescribed biologics and other specialty drugs more frequently-adalimumab (32.7%), apremilast (14.3%), etanercept (11.6%), and ustekinumab (8.8%)-and methotrexate less frequently (30.6%). The greatest unadjusted median health care costs were observed among dermatologists ($45,548) compared with rheumatologists ($30,411), primary care physicians ($29,927), rheumatologists/dermatologists ($27,393), and other specialists ($27,774). However, after adjusting for patient-level factors, multivariate regression analyses found that provider specialty was not associated with higher health care costs.

CONCLUSIONS

In patients with newly diagnosed psoriatic arthritis, physician specialty was associated with different medication choices but not costs.

Для цитирования: Maksabedian Hernandez Ervant J, Tkacz Joseph, Zimmerman Nicole M, Chan Philip, Limone Brendan, Ogdie Alexis, Karis Elaine, Stolshek Bradley. Association of physician specialty with psoriatic arthritis treatment and costs.. The American journal of managed care. 2021. DOI: 10.37765/ajmc.2021.88706.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.